Cytomel (Liothyronine) Cost in North Dakota 2026

What Does Cytomel (Liothyronine) Actually Cost in North Dakota?

The out-of-pocket cost for liothyronine in North Dakota depends heavily on whether you choose brand Cytomel, a generic tablet, or compounded T3. Brand Cytomel lists at approximately $120 per month, but generic liothyronine tablets at North Dakota retail pharmacies average around $35 per month in 2026. Compounded liothyronine from a licensed 503A pharmacy runs about $40 per month.

The gap between the $120 brand list price and the $35 generic cash price exists because multiple manufacturers now produce liothyronine tablets. The FDA maintains an approved drug database showing several generic liothyronine products under the same active-ingredient designation as Cytomel [1]. Switching from brand to generic at the pharmacy counter is the single fastest way to cut costs without changing your dose.

Doses commonly prescribed in North Dakota practices range from 5 mcg once daily up to 50 mcg daily in divided doses. Tablet strength affects unit price modestly, but the monthly cost differential between the 5 mcg and 25 mcg strengths at most North Dakota pharmacies is typically less than $5. Patients on twice-daily dosing protocols do not necessarily pay more than once-daily patients if they split higher-strength tablets, though tablet splitting should only be done with physician approval.

Liothyronine is a synthetic form of triiodothyronine (T3), the biologically active thyroid hormone. Its pharmacokinetics differ from levothyroxine (T4): T3 has a half-life of roughly 1 day compared to levothyroxine's 7-day half-life, which is why divided dosing is common [2]. Understanding that distinction matters for adherence planning and, by extension, for estimating how many tablets you need per month.

How Does North Dakota Medicaid Handle Liothyronine?

North Dakota Medicaid does not cover Cytomel or generic liothyronine for hypothyroidism adjunct therapy. Patients enrolled in the North Dakota Medicaid program who need liothyronine must pay out of pocket or seek a prior-authorization exception, which is rarely granted under current formulary policy.

The North Dakota Department of Human Services administers Medicaid under federal 42 CFR Part 440 guidelines [3]. State Medicaid programs have discretion over which drugs appear on their preferred drug lists, and the ND program generally covers only levothyroxine monotherapy for hypothyroidism. This policy aligns with the mainstream endocrinology position that levothyroxine is first-line treatment for primary hypothyroidism. The American Thyroid Association's 2014 guidelines state that "levothyroxine (LT4) should remain the standard of care for treating hypothyroidism" [4], which gives Medicaid programs a clinical rationale for excluding adjunct T3 therapy from automatic coverage.

Patients whose clinicians believe combination T4/T3 therapy is medically necessary may submit a prior-authorization request documenting failure of levothyroxine monotherapy. The request must include thyroid-stimulating hormone (TSH) history, Free T3 levels, and a clinical note explaining why standard therapy is inadequate. Approval rates for such requests are not publicly reported for North Dakota specifically, but similar state programs approve fewer than 20% of liothyronine prior-authorization submissions, based on published Medicaid utilization data [5].

If Medicaid is your primary coverage and prior authorization fails, the generic cash price of $35 per month may be more accessible than attempting to manage repeated appeals.

Is Compounded Liothyronine Legal in North Dakota?

Compounded liothyronine T3 is legal in North Dakota when prepared by a licensed 503A compounding pharmacy operating under state Board of Pharmacy oversight. The cost runs approximately $40 per month, which is slightly above the generic retail cash price but can offer advantages in dose flexibility.

Under Section 503A of the Federal Food, Drug, and Cosmetic Act, traditional compounding pharmacies may prepare liothyronine in customized strengths not commercially available, provided they compound based on a valid patient-specific prescription [6]. North Dakota follows federal 503A standards and also enforces state Board of Pharmacy regulations for all compounding facilities operating within or shipping into the state. Any out-of-state 503A pharmacy mailing compounded T3 to a North Dakota address must hold a non-resident pharmacy permit issued by the North Dakota Board of Pharmacy.

Compounded liothyronine is not FDA-approved, which means no bioequivalence testing applies to each batch. The FDA has noted variability in potency for some compounded thyroid preparations [7]. For patients who genuinely cannot tolerate commercially available tablet strengths, compounding is a clinically reasonable option under physician supervision. For those who simply want a lower price, the $5 per month premium over generic retail may not justify the switch.

One practical consideration: compounded liothyronine is commonly prepared in sustained-release or time-release capsule formulations. The clinical evidence for sustained-release T3 versus immediate-release tablets is limited. A 1999 trial by Bunevicius et al. published in the New England Journal of Medicine (N=33) showed that substituting 12.5 mcg T3 for 50 mcg T4 in a combination regimen improved mood and neuropsychological function compared with T4 alone [8]. That trial used immediate-release T3, not a sustained-release compound, which is relevant when evaluating what formulation your compounding pharmacy is actually preparing.

Which Insurance Plans Cover Liothyronine in North Dakota?

Commercial insurance coverage for liothyronine in North Dakota varies by plan, but generic liothyronine appears on Tier 1 or Tier 2 formularies at most major carriers. Patients with employer-sponsored insurance through Blue Cross Blue Shield of North Dakota, Sanford Health Plan, or Medica typically pay $10, $25 per month copay for generic liothyronine when it is covered.

Medicare Part D is a separate story. Brand Cytomel is not on most Part D formularies in North Dakota. Generic liothyronine does appear on the formularies of several Part D plans available in the state, usually at the Tier 1 preferred-generic level, meaning a $0, $10 copay per month for patients who have met their deductible [9]. Medicare Advantage plans offered in North Dakota by carriers such as Sanford Medicare Advantage follow their own formulary schedules, so beneficiaries should use the Medicare Plan Finder tool to compare specific plan costs before enrolling.

For brand Cytomel specifically, Pfizer's patient-assistance and co-pay programs may reduce out-of-pocket costs for commercially insured patients. The Pfizer RxPathways program provides co-pay assistance cards for eligible patients, though income and insurance requirements apply [10]. North Dakota patients can apply directly through the Pfizer website or ask their prescriber's office to submit the enrollment paperwork.

Patients who are uninsured or who have a high-deductible plan with no drug benefit before the deductible is met should treat the $35 cash price as their baseline and compare it against any savings card or discount program price before deciding.

What Are the Cheapest Ways to Get Liothyronine in North Dakota?

The cheapest reliable path for most North Dakota patients is generic liothyronine purchased at a large-chain pharmacy using a free drug discount card. Several discount platforms negotiate prices below the standard retail cash price even for drugs that already cost $35 per month, sometimes bringing the price to $15, $22 per month for a 30-day supply.

GoodRx, RxSaver, and NeedyMeds all operate in North Dakota and accept the same basic model: the patient presents a free membership card (digital or printed) at the pharmacy counter, and the pharmacy processes the claim through the discount network rather than through insurance. These cards cannot be combined with insurance in most cases, so patients should compare the discount-card price against their insurance copay before presenting at the counter [11].

Mark Cuban's Cost Plus Drugs platform lists generic liothyronine at a transparent cost-plus-markup price. North Dakota residents with a valid prescription can order through the mail-order service, which may reduce monthly costs further for patients who have reliable mail delivery. Rural North Dakota patients in areas with sparse pharmacy access benefit most from mail-order options.

The 90-day supply pricing model consistently lowers per-tablet cost compared with 30-day fills. Patients who are stable on a fixed dose and have no anticipated dose adjustments should ask their prescribing clinician for a 90-day prescription. This is appropriate only after a stable TSH and Free T3 have been confirmed on the current regimen. The American Thyroid Association recommends TSH monitoring every 6 to 12 months once a patient is stable on thyroid hormone therapy [12].

Below is the HealthRX North Dakota Liothyronine Cost Decision Framework, developed by the HealthRX medical team to help patients and clinicians choose the lowest-cost appropriate supply channel:

Step 1. Confirm whether commercial insurance covers generic liothyronine at a copay below $25/month. If yes, use insurance.

Step 2. If uninsured or the copay exceeds $25/month, check discount-card prices (GoodRx, RxSaver) at the specific North Dakota pharmacy you use. Prices vary by ZIP code.

Step 3. If discount-card prices exceed $22/month for generic tablets, compare Cost Plus Drugs mail-order pricing for a 90-day supply.

Step 4. If your clinician has prescribed a non-standard dose strength that requires compounding, verify the 503A pharmacy's North Dakota licensure before ordering. Budget approximately $40/month.

Step 5. If you are on North Dakota Medicaid and prior authorization was denied, proceed to Step 2 using the $35 cash baseline.

Clinical Evidence Supporting Combination T3 Therapy

Liothyronine prescriptions in North Dakota most commonly come from endocrinologists and primary care physicians managing patients who report persistent hypothyroid symptoms despite normal TSH on levothyroxine alone. The clinical evidence for T3 adjunct therapy is mixed but growing.

The Bunevicius et al. NEJM 1999 trial (N=33) remains the most-cited early evidence. It found statistically significant improvements in mood and cognitive function with combination T4/T3 therapy versus T4 alone, using a crossover design [8]. That trial used immediate-release liothyronine.

A 2019 meta-analysis published in the Journal of Clinical Endocrinology and Metabolism examined seven randomized controlled trials of combination LT4/LT3 therapy versus LT4 monotherapy. The authors concluded that "no consistent benefit in quality of life, mood, or cognitive function was demonstrated across trials," but acknowledged that patient subgroups with specific deiodinase genetic variants (DIO2 polymorphism) may respond differently [13]. This DIO2 angle is central to why some clinicians continue to prescribe liothyronine adjunct therapy even as national guidelines stop short of recommending it broadly.

A 2020 prospective study by Idrees et al. (N=187) found that 49% of patients who preferred combination therapy over monotherapy carried at least one variant allele of DIO2 Thr92Ala [14]. That genetic association, while not yet standard of care for prescribing decisions, gives a biologically plausible rationale for individualized T3 therapy. The Endocrine Society's 2012 clinical practice guideline on thyroid nodules does not address combination therapy directly [15], but the 2014 American Thyroid Association management guidelines note the need for "further research" before combination T4/T3 can be recommended as routine care [4].

For North Dakota patients, the clinical implication is straightforward: liothyronine is prescribed as an adjunct, not a replacement for standard workup and levothyroxine optimization. Any patient pursuing T3 therapy should have documented TSH, Free T4, Free T3, and a discussion of the DIO2 evidence with their prescriber before starting.

Telehealth Prescribing of Liothyronine in North Dakota

Telehealth prescribing of liothyronine is legal in North Dakota for patients who have an established patient-provider relationship. The state does not prohibit prescription of controlled or non-controlled medications via telemedicine when the prescriber holds a valid North Dakota medical license or qualifies under interstate compact provisions [16].

Liothyronine is not a controlled substance. The DEA's scheduling framework does not apply to thyroid hormones, so the additional telehealth restrictions that apply to Schedule II, IV medications, such as those under the Ryan Haight Online Pharmacy Consumer Protection Act, are not relevant here [17]. A licensed physician, nurse practitioner, or physician assistant practicing in North Dakota may prescribe liothyronine after a telemedicine consultation that includes a review of relevant labs (TSH, Free T3, Free T4) and a clinical assessment.

HealthRX provides telehealth consultations for patients in North Dakota. Clinicians on the HealthRX platform can evaluate thyroid lab panels, review symptom history, and prescribe liothyronine when clinically indicated. Prescriptions are sent electronically to the patient's pharmacy of choice, including mail-order pharmacies, so rural North Dakota patients in towns without a local pharmacy can still access this medication.

The North Dakota Board of Medicine requires that telemedicine encounters meet the same standard of care as in-person visits. That means prescribers must document a complete medical history, relevant comorbidities, contraindications (such as untreated adrenal insufficiency or recent myocardial infarction), and a follow-up plan before issuing a liothyronine prescription [18].

Safety Monitoring and Dose Considerations in North Dakota Practice

Liothyronine carries a black-box warning for use in obesity and weight management at doses exceeding physiologic replacement levels. The FDA label explicitly states that thyroid hormones "should not be used for the treatment of obesity or for weight loss" and warns of "serious or life-threatening toxic effects" at large doses in euthyroid patients [19]. North Dakota prescribers are bound by this warning regardless of whether the prescription is written in person or via telehealth.

Standard monitoring after initiating liothyronine includes TSH at 6 weeks after any dose change, Free T3 at 6 weeks if combination therapy is used, and a cardiac assessment in patients over 60 or with pre-existing cardiovascular disease [4]. Heart rate, palpitations, and signs of thyrotoxicosis should be reviewed at every follow-up visit. The American Heart Association has published guidance on thyroid dysfunction and cardiovascular risk, noting that even mild hyperthyroidism (TSH below 0.1 mIU/L) increases atrial fibrillation risk by approximately 3-fold [20].

Patients starting liothyronine in North Dakota should receive a written monitoring schedule from their prescriber. A typical protocol calls for a TSH and Free T3 check at 6 weeks, dose adjustment if needed, and repeat labs at 3 months before transitioning to a stable 6-month monitoring interval.

Liothyronine interacts with several commonly prescribed drugs. Calcium carbonate, iron supplements, and cholestyramine reduce T3 absorption when taken within 4 hours of the dose [21]. Warfarin sensitivity increases with T3, so INR monitoring is required in anticoagulated patients. Amiodarone, a drug used in North Dakota cardiology practices, inhibits T4-to-T3 conversion and complicates thyroid hormone management significantly [22].

North Dakota-Specific Pharmacy Access

North Dakota has 3 pharmacies per 10,000 residents in rural counties, below the national average of 4.6 per 10,000 [23]. For patients in western and central North Dakota, mail-order pharmacy use is not just a cost strategy but a practical necessity. CVS Caremark, Express Scripts, and OptumRx all service North Dakota addresses, and all three carry generic liothyronine.

Walmart pharmacies in Bismarck, Fargo, Grand Forks, and Minot participate in the $4/$10 generic program, and generic liothyronine has appeared on that program's formulary in recent years. Patients should confirm the current Walmart formulary at their specific store location, as the $4 pricing is not guaranteed across all doses or quantities.

Independent pharmacies in North Dakota can also price-match discount-card rates. The North Dakota Pharmacists Association encourages member pharmacies to work with patients on access to affordable medications, and some independent pharmacists will manually apply third-party discount pricing if a patient requests it [24].